“Triple Negative Breast Cancer Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Triple Negative Breast Cancer Market.
The Triple Negative Breast Cancer Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Triple Negative Breast Cancer Pipeline Report:
Companies across the globe are diligently working toward developing novel Triple Negative Breast Cancer treatment therapies with a considerable amount of success over the years.
Triple Negative Breast Cancer companies working in the treatment market are Sichuan Kelun-Biotech Biopharmaceutical, Akeso Biopharma, ProLynx, ModernaTX, Inc., OncoTherapy Science, Phoenix Molecular Designs, Abbisko Therapeutics, BioLite, Inc., Zenith Epigenetics, HiberCell, Inc., Infinity Pharmaceuticals, G1 Therapeutics, Inc, Jiangsu HengRui Medicine Co., Ltd, Shanghai Henlius Biotech, and others, are developing therapies for the Triple Negative Breast Cancer treatment
Emerging Triple Negative Breast Cancer therapies in the different phases of clinical trials are- SKB264, AK117, PLX038, mRNA-2752, OTS167PO, PMD-026, X4P-001, BLEX 404, ZEN003694 +Talazoparib, mprime PGG, IPI-549, Trilaciclib, Camrelizumab, HLX10, and others are expected to have a significant impact on the Triple Negative Breast Cancer market in the coming years.
In January 2025, The Novotech Triple Negative Breast Cancer Clinical Trial Report highlighted ongoing drug development across multiple phases, with 78 trials in Phase I, 97 in Phase II, and 12 in Phase III. Key advancements include targeted therapies such as PARP inhibitors, immune checkpoint inhibitors (ICIs), and innovative antibody-drug conjugates (ADCs). Additionally, combination approaches that integrate immunotherapy, chemotherapy, and targeted treatments are improving overall treatment effectiveness.
In November 2024, A novel treatment strategy developed at Roswell Park Comprehensive Cancer Center demonstrated encouraging results in a Phase 1 clinical trial for patients with triple-negative breast cancer (TNBC), the most aggressive form of the disease.
In February 2024, Trodelvy (sacituzumab govitecan-hziy) is the first approved antibody-drug conjugate for treating advanced triple-negative breast cancer (TNBC) in adults who have undergone at least two prior treatments for metastatic disease. It is also indicated for pre-treated HR+/HER2- metastatic breast cancer patients and second-line metastatic TNBC patients who have received endocrine-based therapy and at least two other systemic therapies.
Triple Negative Breast Cancer Overview
Triple Negative Breast Cancer (TNBC) is characterized by a tumor that has negative levels of estrogen and progesterone (ER/PR), as determined by immunohistochemistry (IHC), and neither immunohistochemistry (IHC) nor fluorescence in situ hybridization (FISH) has detected overexpression of the HER2 gene.
Get a Free Sample PDF Report to know more about Triple Negative Breast Cancer Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/triple-negative-breast-cancer-tnbc-pipeline-insight
Emerging Triple Negative Breast Cancer Drugs Under Different Phases of Clinical Development Include:
SKB264: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
AK117: Akeso Biopharma
PLX038: ProLynx
mRNA-2752: ModernaTX, Inc.
OTS167PO: OncoTherapy Science
PMD-026: Phoenix Molecular Designs
X4P-001: Abbisko Therapeutics
BLEX 404: BioLite, Inc.
ZEN003694 +Talazoparib: Zenith Epigenetics
mprime PGG: HiberCell, Inc.
IPI-549: Infinity Pharmaceuticals
Trilaciclib: G1 Therapeutics, Inc
Camrelizumab: Jiangsu HengRui Medicine Co., Ltd
HLX10: Shanghai Henlius Biotech
Triple Negative Breast Cancer Route of Administration
Triple Negative Breast Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
Oral
Parenteral
Intravenous
Subcutaneous
Topical
Triple Negative Breast Cancer Molecule Type
Triple Negative Breast Cancer Products have been categorized under various Molecule types, such as
Monoclonal Antibody
Peptides
Polymer
Small molecule
Gene therapy
Triple Negative Breast Cancer Pipeline Therapeutics Assessment
Triple Negative Breast Cancer Assessment by Product Type
Triple Negative Breast Cancer By Stage and Product Type
Triple Negative Breast Cancer Assessment by Route of Administration
Triple Negative Breast Cancer By Stage and Route of Administration
Triple Negative Breast Cancer Assessment by Molecule Type
Triple Negative Breast Cancer by Stage and Molecule Type
DelveInsight’s Triple Negative Breast Cancer Report covers around 80+ products under different phases of clinical development like
Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration
Further Triple Negative Breast Cancer product details are provided in the report. Download the Triple Negative Breast Cancer pipeline report to learn more about the emerging Triple Negative Breast Cancer therapies
Some of the key companies in the Triple Negative Breast Cancer Therapeutics Market include:
Key companies developing therapies for Triple Negative Breast Cancer are – ModernaTX, Inc, NuGenerex Immuno-Oncology, Pfizer, Jiangsu Alphamab Biopharmaceuticals Co., Ltd., BioLite, Inc., ImmunityBio, Inc., PharmAbcine, Genexine, Inc., CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Novartis Pharmaceuticals, Klus Pharma, Ayala Pharmaceuticals, Inc, Shanghai Henlius Biotech, Jiangsu HengRui Medicine Co., Ltd., G1 Therapeutics, Inc., Infinity Pharmaceuticals, HiberCell, Inc., Zenith Epigenetics, BioLite, Inc., Abbisko Therapeutics, Phoenix Molecular Designs, OncoTherapy Science, Akeso Biopharma, Chipscreen Biosciences, OncoPep, Inc., Iovance Biotherapeutics, Inc., SynDevRx, Inc., Hoffmann-La Roche, Celcuity, Inc., Amgen, AstraZeneca, NBE-Therapeutics AG, Fusion Pharmaceuticals, Immutep Limited, and others.
Triple Negative Breast Cancer Pipeline Analysis:
The Triple Negative Breast Cancer pipeline report provides insights into
The report provides detailed insights about companies that are developing therapies for the treatment of Triple Negative Breast Cancer with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Triple Negative Breast Cancer Treatment.
Triple Negative Breast Cancer key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Triple Negative Breast Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Triple Negative Breast Cancer market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Triple Negative Breast Cancer drugs and therapies
Triple Negative Breast Cancer Pipeline Market Drivers
Increase in the prevalence of Triple Negative Breast Cancer, increasing Research and Development activities are some of the important factors that are fueling the Triple Negative Breast Cancer Market.
Triple Negative Breast Cancer Pipeline Market Barriers
However, high cost of the treatment, side effects associated with the treatment and other factors are creating obstacles in the Triple Negative Breast Cancer Market growth.
Scope of Triple Negative Breast Cancer Pipeline Drug Insight
Coverage: Global
Key Triple Negative Breast Cancer Companies: Sichuan Kelun-Biotech Biopharmaceutical, Akeso Biopharma, ProLynx, ModernaTX, Inc., OncoTherapy Science, Phoenix Molecular Designs, Abbisko Therapeutics, BioLite, Inc., Zenith Epigenetics, HiberCell, Inc., Infinity Pharmaceuticals, G1 Therapeutics, Inc, Jiangsu HengRui Medicine Co., Ltd, Shanghai Henlius Biotech, and others
Key Triple Negative Breast Cancer Therapies: SKB264, AK117, PLX038, mRNA-2752, OTS167PO, PMD-026, X4P-001, BLEX 404, ZEN003694 +Talazoparib, mprime PGG, IPI-549, Trilaciclib, Camrelizumab, HLX10, and others
Triple Negative Breast Cancer Therapeutic Assessment: Triple Negative Breast Cancer current marketed and Triple Negative Breast Cancer emerging therapies
Triple Negative Breast Cancer Market Dynamics: Triple Negative Breast Cancer market drivers and Triple Negative Breast Cancer market barriers
Request for Sample PDF Report for Triple Negative Breast Cancer Pipeline Assessment and clinical trials
Table of Contents
1. Triple Negative Breast Cancer Report Introduction
2. Triple Negative Breast Cancer Executive Summary
3. Triple Negative Breast Cancer Overview
4. Triple Negative Breast Cancer- Analytical Perspective In-depth Commercial Assessment
5. Triple Negative Breast Cancer Pipeline Therapeutics
6. Triple Negative Breast Cancer Late Stage Products (Phase II/III)
7. Triple Negative Breast Cancer Mid Stage Products (Phase II)
8. Triple Negative Breast Cancer Early Stage Products (Phase I)
9. Triple Negative Breast Cancer Preclinical Stage Products
10. Triple Negative Breast Cancer Therapeutics Assessment
11. Triple Negative Breast Cancer Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Triple Negative Breast Cancer Key Companies
14. Triple Negative Breast Cancer Key Products
15. Triple Negative Breast Cancer Unmet Needs
16 . Triple Negative Breast Cancer Market Drivers and Barriers
17. Triple Negative Breast Cancer Future Perspectives and Conclusion
18. Triple Negative Breast Cancer Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Gaurav BoraEmail: Send EmailPhone: +14699457679Address:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/